Organogenesis (ORGO) Competitors $4.40 -0.06 (-1.35%) Closing price 04:00 PM EasternExtended Trading$4.44 +0.04 (+1.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. HRMY, ADPT, SPRY, CNTA, TARS, BEAM, SRPT, ARQT, IMCR, and SDGRShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Harmony Biosciences Adaptive Biotechnologies ARS Pharmaceuticals Centessa Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics Sarepta Therapeutics Arcutis Biotherapeutics Immunocore Schrodinger Organogenesis (NASDAQ:ORGO) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Which has more volatility & risk, ORGO or HRMY? Organogenesis has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ORGO or HRMY? 49.6% of Organogenesis shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 33.0% of Organogenesis shares are held by insiders. Comparatively, 23.6% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to ORGO or HRMY? In the previous week, Harmony Biosciences had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Harmony Biosciences and 3 mentions for Organogenesis. Harmony Biosciences' average media sentiment score of 0.94 beat Organogenesis' score of 0.35 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ORGO or HRMY? Organogenesis currently has a consensus target price of $6.00, suggesting a potential upside of 36.36%. Harmony Biosciences has a consensus target price of $51.33, suggesting a potential upside of 49.53%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Harmony Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ORGO or HRMY more profitable? Harmony Biosciences has a net margin of 20.53% compared to Organogenesis' net margin of -3.46%. Harmony Biosciences' return on equity of 24.32% beat Organogenesis' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-3.46% -4.00% -2.26% Harmony Biosciences 20.53%24.32%15.92% Which has better valuation and earnings, ORGO or HRMY? Harmony Biosciences has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.16$860K-$0.17-25.88Harmony Biosciences$714.73M2.76$145.49M$2.6213.10 SummaryHarmony Biosciences beats Organogenesis on 15 of the 17 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$565.77M$2.43B$5.56B$9.04BDividend YieldN/A1.79%5.25%4.03%P/E Ratio-25.889.3827.1820.14Price / Sales1.16765.58440.78137.14Price / Cash21.37164.1737.5058.41Price / Book2.114.698.085.60Net Income$860K$31.26M$3.16B$248.43M7 Day Performance1.15%6.81%3.77%5.15%1 Month Performance26.80%4.12%3.90%7.62%1 Year Performance53.85%4.05%34.22%21.56% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.2874 of 5 stars$4.40-1.3%$6.00+36.4%+60.4%$565.77M$482.04M-25.88950HRMYHarmony Biosciences4.8116 of 5 stars$31.60-1.2%$53.63+69.7%-0.8%$1.84B$714.73M12.06200News CoverageAnalyst ForecastADPTAdaptive Biotechnologies3.4352 of 5 stars$11.65-1.2%$10.57-9.3%+237.0%$1.79B$178.96M-12.14790SPRYARS Pharmaceuticals3.0794 of 5 stars$17.45-4.1%$31.00+77.7%+83.4%$1.79B$89.15M-109.0690High Trading VolumeCNTACentessa Pharmaceuticals2.6282 of 5 stars$13.14+0.1%$27.89+112.2%+43.3%$1.75B$6.85M-7.26200TARSTarsus Pharmaceuticals2.1391 of 5 stars$40.51+0.4%$66.67+64.6%+46.0%$1.70B$182.95M-14.8450Positive NewsBEAMBeam Therapeutics2.6909 of 5 stars$17.01+1.3%$48.75+186.6%-10.0%$1.69B$63.52M-3.69510News CoverageGap UpSRPTSarepta Therapeutics4.7609 of 5 stars$17.10-0.1%$60.88+256.0%-87.1%$1.68B$1.90B-6.361,372Trending NewsAnalyst ForecastHigh Trading VolumeARQTArcutis Biotherapeutics1.2132 of 5 stars$14.02+2.0%$18.80+34.1%+41.9%$1.64B$196.54M-13.48150IMCRImmunocore1.1702 of 5 stars$31.38+0.8%$58.89+87.7%-9.7%$1.56B$310.20M-72.98320SDGRSchrodinger2.6805 of 5 stars$20.12-2.4%$32.80+63.0%+5.7%$1.51B$207.54M-7.65790High Trading Volume Related Companies and Tools Related Companies Harmony Biosciences Alternatives Adaptive Biotechnologies Alternatives ARS Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Beam Therapeutics Alternatives Sarepta Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Immunocore Alternatives Schrodinger Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
